Want $1 million in retirement? Invest $10,000 in these 2 AI stocks and hold for 10 years.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.
GEN

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
FierceBiotech

AI drug prospector Recursion bumps IPO up (again) to $374M

Recursion Pharmaceuticals ramped up its IPO target from $100 million to $306 million earlier this week, but the artificial intelligence biotech is scratching that plan. Now, it’s aiming to raise $374 ...
Forbes

Biotech Recursion Pharma Drops Back To IPO Price — Again.

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...
Business Wire

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...